For the past few years, GLP-1 medicines such as semaglutide and tirzepatide have reshaped the way obesity is treated. What began as a diabetes treatment has become one of the most talked-about developments in modern healthcare. But the field is far from standing still. New formats, new science and new questions are emerging quickly — so here is a clear, balanced look at where things are heading.
Oral Wegovy and the rise of the weight-loss pill
One of the biggest shifts is the move away from the needle. Injectable treatments have proven highly effective, but for many people the idea of a weekly injection is a genuine barrier. Oral versions of semaglutide have been studied in large clinical trials, with higher-dose tablets showing meaningful weight reduction for some patients.
The appeal is obvious: a daily tablet is familiar, discreet and far less daunting for needle-averse patients. As oral options move through the regulatory process in different markets, they could open weight-management support to a much wider group of people. Availability varies and is changing rapidly, so it is always worth checking what is currently licensed and accessible in the UK.
Beyond GLP-1: the next generation of “multi-pathway” treatments
The first GLP-1 medicines worked on a single hormonal pathway. The newer wave aims to do more by targeting several at once:
- Dual agonists (GIP/GLP-1): Tirzepatide acts on two gut-hormone pathways at the same time, which in trials has been associated with substantial weight loss.
- Triple agonists: Experimental treatments that add a third pathway (glucagon) are being studied, with early trial data attracting significant attention.
- Amylin analogues: Drugs that mimic the hormone amylin, sometimes combined with semaglutide, are in development as another route to appetite control.
It is important to note that several of these are still in trials and not yet routinely available. The direction of travel, however, is clear: more options, aiming for greater effect and better tolerability.
What happens after you stop?
Perhaps the most important conversation is about the long term. These medicines treat a chronic condition — they are not a short course. Research has consistently shown that when treatment stops, appetite signals return and a significant proportion of the lost weight tends to come back. One widely cited study found participants had regained much of their weight in the year after stopping.
This does not mean the medicines “don’t work”. It means weight management is an ongoing process, and any decision to start, change or stop treatment should be planned with a healthcare professional, alongside sustainable changes to diet, activity and lifestyle.
The takeaway
The pace of innovation is genuinely exciting, but the fundamentals haven’t changed: these are powerful medicines that work best as part of a supported, long-term plan. If you are considering weight-loss treatment, our Weight Management service and pharmacy team can talk you through the options safely — book a weight loss consultation to find out what is right for you.
Medical disclaimer: This article is for general information only and is not a substitute for professional medical advice. Prescription weight-loss medicines are not suitable for everyone. Always speak to a pharmacist, GP or prescriber before starting, changing or stopping any treatment.